Malta - English - Medicines Authority

as grindeks krustpils iela 53 riga, lv-1057 , latvia - tablet - sulpiride 50 mg - psycholeptics

Malta - English - Medicines Authority

as grindeks krustpils iela 53 riga, lv-1057 , latvia - tablet - sulpiride 100 mg - psycholeptics

Malta - English - Medicines Authority

as grindeks krustpils iela 53 riga, lv-1057 , latvia - tablet - sulpiride 300 mg - psycholeptics

Canada - English - Health Canada

dolisos laboratoires s.a. - origanum majorana - drops - 1dh - origanum majorana 1dh - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - origanum majorana - globules - 1x - origanum majorana 1x - homeopathic products

United States - English - NLM (National Library of Medicine)

ariad pharmaceuticals inc. - brigatinib (unii: hyw8db273j) (brigatinib - unii:hyw8db273j) - brigatinib 30 mg - alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) who have progressed on or are intolerant to crizotinib. this indication is approved under accelerated approval based on tumor response rate and duration of response [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. none. risk summary based on its mechanism of action and findings in animals, alunbrig can cause fetal harm when administered to a pregnant woman [see data and clinical pharmacology (12.1)] . there are no clinical data on the use of alunbrig in pregnant women. administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by auc at 180 mg once daily) as well as increased post-implantation loss, malformatio

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - brigatinib (unii: hyw8db273j) (brigatinib - unii:hyw8db273j) - brigatinib 30 mg - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test [see dosage and administration (2.1)] . none. risk summary based on its mechanism of action and findings in animals, alunbrig can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no clinical data on the use of alunbrig in pregnant women. administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by auc at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated back

United States - English - NLM (National Library of Medicine)

washington homeopathic products -   origanum - to relieve the symptoms of impulsiveness. indications: origanum   impulsiveness if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - origanum - to relieve the symptoms of impulsiveness. indications:  origanum   impulsiveness if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

Malta - English - Medicines Authority

as grindeks krustpils iela 53 riga, lv-1057 , latvia - lenalidomide - hard capsule - lenalidomide 2.5 mg - immunosuppressants